Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07379827 · ClinicalTrials.gov registry record

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

A clinical trial of Schizophrenia, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
1,500
Enrollment target
20
Study locations

NCT07379827 is a study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,500 participants, above the 214-participant average among 315 other Schizophrenia trials with a reported enrollment target (601% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07379827, a study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
1,500 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

Conditions Studied

Schizophrenia

Interventions

  • DRUG Xanomeline and trospium chloride (KarXT)

Study Locations (20)

Florida

  • Local Institution - 0005 - Bonita Springs
  • Local Institution - 0019 - Hialeah
  • Local Institution - 0030 - Homestead
  • Local Institution - 0029 - Kendall
  • Local Institution - 0032 - Miami
  • Local Institution - 0011 - Miami
  • Local Institution - 0007 - Miami
  • Local Institution - 0006 - Miami
  • Local Institution - 0023 - Orange City

California

  • Local Institution - 0003 - Anaheim
  • Local Institution - 0012 - La Palma
  • Local Institution - 0028 - Stanford

New York

  • Local Institution - 0004 - Monsey
  • Local Institution - 0020 - White Plains

Arkansas

  • Local Institution - 0009 - Bryant

Georgia

  • Local Institution - 0025 - Atlanta

Michigan

  • Local Institution - 0014 - Bloomfield Township

North Carolina

  • PPD Virtual - PPD - US - Wilmington

Ohio

  • Local Institution - 0031 - Mason

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2026-02-26
Est. Completion 2028-06-20

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07379827

The ClinicalTrials.gov registry entry for NCT07379827 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 214-participant average among 315 other Schizophrenia trials with a reported enrollment target (601% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Xanomeline and trospium chloride (KarXT) is the first listed.

NCT07379827 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT07379827 about?

NCT07379827 is a clinical study titled "Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)". The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

What is the current status of trial NCT07379827?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2026-02-26. Estimated completion is 2028-06-20.

What conditions does trial NCT07379827 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07379827?

The interventions under investigation include: Xanomeline and trospium chloride (KarXT) (DRUG).

Who is sponsoring clinical trial NCT07379827?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07379827 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.